Trials / Completed
CompletedNCT02112110
Absolute Bioavailability of BMS-791325
Study of the Absolute Oral Bioavailability of BMS-791325 in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years – 49 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to determine the absolute bioavailability of 150 mg oral dose of BMS-791325 relative to 100 µg IV infusion of \[13C\]-BMS-791325.
Detailed description
Primary Purpose: Other: Protocol is designed to assess the absolute bioavailability of 150 mg (2x75 mg tablets) BMS-791325 administered orally
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-791325 | |
| DRUG | [13C]-BMS-791325 |
Timeline
- Start date
- 2014-04-01
- Primary completion
- 2014-05-01
- Completion
- 2014-05-01
- First posted
- 2014-04-11
- Last updated
- 2014-06-26
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT02112110. Inclusion in this directory is not an endorsement.